Kymera Therapeutics (KYMR) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Chairperson welcomed attendees, introduced board members, executive team, and independent auditor.
Outlined meeting procedures and confirmed agenda as set forth in the 2024 Notice of Annual Meeting and Proxy Statement.
Board and executive committee updates
Introduced all board members and executive officers present at the meeting.
Shareholder proposals
Four proposals presented: election of Class I Directors, advisory vote on executive compensation, ratification of independent auditor, and amendment to the 2020 Stock Option and Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kymera Therapeutics
- Oral degraders advance as transformative therapies for immunology and oncology, targeting major unmet needs.KYMR
Corporate presentation - KT-621 and KT-579 progress rapidly; $65M Q2 revenue, $61.2M net loss, $1.5B cash runway.KYMRQ2 2026
- STAT6 and IRF5 programs drive pipeline growth, targeting large unmet needs in Type 2 diseases.KYMROppenheimer 36th Annual Healthcare Life Sciences Conference
- Oral degraders advance in AD and asthma, showing strong efficacy and safety in early trials.KYMR44th Annual J.P. Morgan Healthcare Conference
- Accelerated immunology pipeline targets broad indications with strong biomarker and clinical strategy.KYMRCiti Annual Global Healthcare Conference 2025
- KT-474 Phase 2 expansion, strong pipeline data, and $702M cash runway highlight Q2 2024.KYMRQ2 2024
- Q3 net loss of $62.5M; $911M cash supports immunology focus and clinical milestones into 2027.KYMRQ3 2024
- KT-621 achieved >90% STAT6 degradation, strong Th2 biomarker reduction, and excellent safety.KYMRStudy Result
- KT-621 and TYK2 degraders advance with pivotal trials and major data readouts set for 2024.KYMRTD Cowen 45th Annual Healthcare Conference
- Pipeline advanced, strong cash reserves, and major clinical milestones expected in 2025.KYMRQ4 2024